Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Dechra Pharmaceuticals PLC specializes in veterinary pharmaceuticals, particularly in the development and marketing of prescription medications for companion animals and livestock. Its strong presence in Europe and North America, coupled with a diverse product portfolio including anti-infectives and analgesics, positions it uniquely in the growing animal health market.
Dechra generates revenue primarily through the sale of prescription medications and nutraceuticals for pets and livestock. The company benefits from strong pricing power due to its specialized product offerings and established relationships with veterinarians, allowing it to maintain high gross margins.
Regulatory approvals for new veterinary drugs
Market expansion in North America and Europe
Acquisitions of complementary businesses
Changes in pet ownership trends and spending on animal health
Regulatory changes affecting drug approvals and market access
Technological disruption in veterinary medicine and treatment options
Intense competition from larger pharmaceutical companies
Emergence of generic alternatives for key products
Negative net margin (-3.7%) indicating potential cash flow issues
Dependence on continued investment in R&D to sustain product pipeline
moderate - The demand for veterinary pharmaceuticals is somewhat resilient during economic downturns, but overall consumer spending on pet care can be affected by economic conditions.
Interest rates can impact Dechra's financing costs for potential acquisitions and R&D investments. Higher rates may also pressure consumer spending on discretionary pet care products.
minimal - Dechra's debt-to-equity ratio of 0.67 indicates manageable debt levels, reducing reliance on credit conditions.
growth - Investors are likely attracted to Dechra's potential for revenue growth in the expanding animal health market.
moderate - The stock has shown a 1-year return of 31.9%, indicating some volatility but also strong performance.
